Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 9, Regeneron ...

These are the first clinical study results for the drug in a large population of patients with darker skin tones ...

Sanofi presents positive results from DISCOVER phase 4 study of Dupixent in atopic dermatitis patients with skin of colour at 2025 RAD conference: Paris Tuesday, June 10, 2025, 16 ...

Regeneron and Sanofi have announced promising outcomes from the open-label Phase IV DISCOVER trial of Dupixent (dupilumab).

Sanofi boosts Beyfortus output for RSV season while Dupixent trial shows strong eczema relief in patients with skin of color.

US biotech Regeneron Pharmaceuticals (Nasdaq: REGN) and French pharma major Sanofi (Euronext: SAN) on Saturday presented ...

TARRYTOWN, N.Y. and PARIS, June 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: REGN) and Sanofi today presented results from the DISCOVER Phase 4, single-arm, open-label trial assessing Dupixent ® (dupilumab) ...

The investigational drug demonstrated robust STAT6 degradation in blood and skin that was well tolerated and safe in healthy ...

Kymera Therapeutics reported positive results from its phase 1 healthy volunteer study using KT-621. Click here to find out why KYMR stock is a Strong Buy.

Regeneron Pharmaceuticals (REGN) reported interim results from a mid-stage trial testing combinations of semaglutide with experimental antibodies, trevogrumab and garetosmab, for treating obesity.

Kymera Therapeutics, Inc. (NASDAQ:KYMR) on Monday revealed clinical results from the Phase 1 healthy volunteer study of ...

Triple combo therapy cut 30 pounds with just 2 lbs of lean mass lost, showing strong fat-targeting results in the midstage trial. Regeneron inks $80 million deal with Hansoh for Phase 3 obesity ...